Best Practices in Fibromyalgia Diagnosis and Multimodal Management: Insights from the Fibromyalgia Working Group
- Credit Type
- CME
- Credit Amount
- 1
- Release Date
- 07/01/2010
- Expiration Date
- 06/30/2011
- Activity Type
- Monograph
Jointly sponsored by Albert Einstein College of Medicine and Montefiore Medical Center, and Asante Communications
This activity is supported by an educational grant from Pfizer, Inc.
Activity Goal
The goal of this activity is to disseminate best practices in the individualized assessment and management of patients with fibromyalgia.
Intended Audience
This activity is intended for pain specialists, rheumatologists, primary care physicians, physician assistants, nurse practitioners, and other health care providers interested in improving their knowledge base and skill sets in the individualized assessment and management of patients with fibromyalgia.
Method Participation
There are no fees for participating in and receiving credit for this activity. Participants should complete the activity and mail the posttest, activity evaluation, and self-report credit form on pages 11 and 12 to CCME, 3301 Bainbridge Avenue, Bronx, NY 10467, or fax to 718-798-2336. Certificates will be mailed approximately 6 to 8 weeks after receipt of mailed/faxed submissions. Credit is available for this educational activity from July 1, 2010 through June 30, 2011.
Learning Objectives
At the conclusion of this initiative, participants will be better prepared to:
• Describe current insights into the pathogenesis of fibromyalgia and how they inform practical considerations for treatment
• Conduct multidimensional and continual assessment of patients with suspected fibromyalgia based in part on signs and symptoms of enhanced sensory processing
• Utilize semi-structured interviews in patients with fibromyalgia to characterize biopsychosocial impairment and individualize therapy accordingly
• Explain putative mechanisms by which pharmacologic agents achieve analgesic effects in patients with fibromyalgia
• Formulate multimodal treatment strategies tailored to the complex symptomatology of patients with fibromyalgia
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine and Montefiore Medical Center, and Asante Communications. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Albert Einstein College of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Conflict of Interest Statement
The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenters whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.
Charles E. Argoff, MD
Eli Lilly and Company (grant/research, consultant, speakers bureau); Endo Pharmaceuticals (grant/research, consultant, speakers bureau); Forest Laboratories, Inc (grant/research, consultant, speakers bureau); King Pharmaceuticals, Inc (consultant, speakers bureau); Pfizer Inc (grant/research, consultant, speakers bureau, stockholder); PriCara (consultant, speakers bureau)
Lesley M. Arnold, MD
Allergan, Inc. (grant/research, consultant); AstraZeneca US (consultant); Boehringer Ingelheim (grant/research, consultant); Cypress Bioscience, Inc. (grant/research, consultant); Eli Lilly and Company (grant/research, consultant); Forest Laboratories, Inc (grant/research, consultant, speakers bureau); Pfizer Inc (grant/research, consultant); Sanofi-aventis U.S. LLC (consultant); Takeda Pharmaceutical Company Limited (consultant); Theravance, Inc. (consultant); UCB S.A. (consultant); Wyeth (grant/research, consultant)
Peter Barland, MD
Dr Barland has no conflicts of interest to report
Kurt Kroenke, MD
Eli Lilly and Company (consultant); Forest Laboratories, Inc (consultant)
I. Jon Russell, MD, PhD
Allergan, Inc. (grant/research, consultant); AstraZeneca US (consultant); Boehringer Ingelheim (grant/research, consultant); Cypress Bioscience, Inc. (grant/research, consultant); Eli Lilly and Company (grant/research, consultant); Forest Laboratories, Inc (grant/research, consultant, speakers bureau); Pfizer Inc (grant/research, consultant); Sanofi-aventis U.S. LLC (consultant); Takeda Pharmaceutical Company Limited (consultant); Theravance, Inc. (consultant); UCB S.A. (consultant); Wyeth(grant/research, consultant)
Albert Einstein College of Medicine staff and the staff of Asante Communications have no conflicts of interest with commercial interests related directly or indirectly to this educational activity (except as noted below).
Steven Jay Feld of Albert Einstein College of Medicine, or a member of his household, owns securities in Bioheart, Inc.; Chelsea Therapeutics, Inc.; and Pharmacopeia, Inc.
Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. These materials discuss off-label uses of approved products including opioids, nonsteroidal anti-inflammatory drugs, gabapentin, tricyclic antidepressants, cyclobenzaprine, sodium oxybate, and tramadol. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright Information
Copyright © 2010 Albert Einstein College of Medicine and Montefiore Medical Center, and Asante Communications.
All rights reserved. No part of this monograph may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.
References
- Chakrabarty S, Zoorob R. Fibromyalgia. Am Fam Physician. 2007;76(2):247-254.
- Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum. 2008;58:26-35.
- Greenberg PE, Leong SA, Birnbaum HG, et al. The economic burden of depression with painful symptoms. J Clin Psychiatry.2003;64(suppl 7):17-23.
- Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Psychiatric comorbidities in acommunity sample of women with fibromyalgia. Pain. 2006;124(1-2):117-125.
- Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol.2006;12(3):124-128.
Faculty
